Gancliclovir is an IV drug that has been shown to decrease the chances of hearing loss in infants with congenitgal cytomegalovirus (CMV). Since CMV-assocaitged hearing loss often emerges after infancy, there is an unmet need for a treatment option for the toddler population. Valganciclovir is the oral form of ganciclovir and we would like to see if giving toddlers with hearing loss and congenital CMV valganciclovir for 6 weeks will stabilize hearing loss.
Who may be Eligible
Ages 1 month through 3 years old; diagnosed with sensorineural hearing loss (SNHL); diagnosed with CMV